domingo, 14 de marzo de 2021

Dr. House y Viopril story /Etica


Edward Vogler was a billionaire owner of a pharmaceutical company who donated a large sum of money to Princeton-Plainsboro. He became the new Chairman of The Board. He disliked House and went to great efforts to get him fired. His dad had given him $20,000 for college, which he would have realized was a mistake had he known that Vogler was not actually in college. Vogler accepted the money and he invested it in a friend who owned a small business. The business made a lot of money making Vogler a multi-millionaire. He called his dad who was upset with him for not telling him that he was not in college; the two did not speak for a while. He next decided to invest the money in more businesses, all of which were incredibly successful. Vogler went public and became a billionaire overnight. He went to see his dad, where Vogler told him about all the money he had made with the money that he had received from him, but his father said nothing. It turned out that he didn't recognize Vogler because his Alzheimer's had taken a turn for the worst.

So Vogler decided to donate $100 million to PPTH, ostensibly to help cure diseases such as Alzheimer's disease and cancer. However, his condition was to become chairman of the board of directors in order to control what his money was spent on. He took an immediate dislike to House, at first for his consistent failure to wear a lab coat, but then after he noted that House brought in very little income for the money he spent.

Robert Chase agreed to spy on House for Vogler, essentially in a bid to save his own job. Vogler then demanded that House fire one of his fellows to save money. Cameron came up with the idea of having everyone take a pay cut, but although House offered Vogler the option, Vogler turned it down - what he really wanted was to let House know that he was no longer calling the shots on his team. Without knowing of Chase's betrayal, House finally chose to fire Chase, but Vogler told him at that point he had to fire either Cameron or Foreman as, although Vogler had tried to get both Cameron and Foreman to replace Chase as his snitch, they had both refused.


Tres capítulos atrás Vogler, dueño de una empresa farmacéutica, había asumido como nuevo presidente del Hospital Escuela Princeton-Plainsboro con la filosofía de gestionarlo como si fuera un negocio y de inmediato chocó frontalmente con el Dr. House.

En el capítulo siguiente Vogler le ordenó a House despedir a uno de los tres médicos de su equipo. En este capítulo Vogler le ofrece dejar sin efecto la orden de despedir a uno de los médicos si pronuncia un discurso elogiando un nuevo medicamento de su empresa. House no desea apoyar el nuevo medicamento porque se trata de un método repudiable de las empresas farmacéuticas de agregar un nuevo componente secundario para poder mantener la patente y aumentar los precios, sin ninguna razón médica.


However, Vogler gave House one more chance - if House would agree to give a talk saying how wonderful one of Vogler's new drugs was, he would agree to keep everyone on.


House agreed, to the astonishment of his team and the relief of Wilson and Cuddy. 

However, House soon realized that Vogler's new drug, called Viopril (fictive), was merely an expensive alternative to a cheap medication to which Vogler had added nothing more than an antacid. Instead of giving Vogler's impressive speech, House explained to the astonished audience and a stunned Vogler that they should continue to use the old cheap drug, because it was just as good. As a result, Cameron agreed to leave the team. In addition, House figured out that Chase was the snitch and, since he couldn't fire him, had to live with the fact.(Más)


Dr. House T1-17 Role Model

Vogler: [as House is leaving] Oh, and by the way, I need you to give a speech at the National Cardiology Conference. Next week.

House: I don’t do speeches. I’m shy.

Vogler: Eastbrook Pharmaceuticals has developed a new ACE inhibitor. I would like you to extol the virtues of this breakthrough medication.

House: Eastbrook Pharmaceuticals… wait a second, don’t I own that company? Oh, no, that’s right, you do.

Vogler: Viopril is a significant improvement over the old version. All there in the study. [He hands House a booklet of information.]

House: I know its price tag is significantly improved.

House MD - 1.17 Role Model

No hay comentarios: